Akso Health Group: Form 20-F for the period ended Mar 31, 2025
Filed with the SEC on Aug 14, 2025 and accepted by EDGAR at Aug 14, 2025, 17:29 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-04-01 to 2025-03-31 | $14.8m | us-gaap:Revenues |
| Cost of revenue | 12 months2024-04-01 to 2025-03-31 | $15.1m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2024-04-01 to 2025-03-31 | −$281.5k | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months2024-04-01 to 2025-03-31 | $3.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2024-04-01 to 2025-03-31 | −$166.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2024-04-01 to 2025-03-31 | −$30.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-04-01 to 2025-03-31 | −$135.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-04-01 to 2025-03-31 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-04-01 to 2025-03-31 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-04-01 to 2025-03-31 | 855,288,335 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-04-01 to 2025-03-31 | $1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-04-01 to 2025-03-31 | $154.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-03-31 | $176.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $196.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $215.0m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $13.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $15.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-03-31 | $199.1m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-03-31 | 1,655,583,530 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-25-076862. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.